AstraZeneca (AZN)
Anglo-Swedish pharmaceutical company formed by the 1999 merger of Astra AB and Zeneca Group, with major franchises in oncology, cardiovascular and rare diseases. One of the largest companies on the London Stock Exchange.
- Legal name
- AstraZeneca PLC
- Ticker
- AZN
- Exchange
- London Stock Exchange · MIC XLON
- Country
- United Kingdom
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Market cap ≈
- $252.2bn — computed, not copied: 1.551bn shares × 11970 GBp close on 2026-08-28
- Reporting currency
- GBP
- Founded
- 1999
- Website
- www.astrazeneca.com
- LEI
- PY6ZZQWO2IZFZC3IOL08 (GLEIF)
- ISIN
- GB0009895292 (check digit validated)
- FIGI
- BBG001SCNW31 (share class, OpenFIGI)
Graph connections view in graph →
lists_onLondon Stock Exchange
domiciled_inUnited Kingdom
member_ofFTSE 100
Sector peers — Healthcare
Eli Lilly · UnitedHealth Group · Johnson & Johnson · AbbVie · Merck & Co. · Thermo Fisher Scientific
Compare: AZN vs LLY · AZN vs UNH · AZN vs JNJ
How this market cap is arrived at
| Shares outstanding | 1,550,957,927 |
| Basis | outstanding |
| As of | 2025-12-31 |
| Source | SEC 20-F cover page (2025-12-31) |
| Price | 11970 GBp · AZN.L · close 2026-08-28 |
| Venue | LSE |
| Converted at | ECB euro reference rates, 2026-08-28 |
| Market cap | $252.2bn |
ADR programme terminated - this is the big trap. Shareholders approved listing harmonisation on 3 Nov 2025 and it took effect 2 February 2026: AstraZeneca's ordinary shares of US$0.25 are now listed directly on the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange, all under the symbol AZN (AstraZeneca Annual Report & Form 20-F 2025, 'Shareholder information').
Share counts move on a filing cadence, prices move continuously — so this figure is exact only as of the two dates above, and we publish both rather than a single undated number. This company is quoted here through a depositary receipt (AZN), where one receipt represents 1 ordinary share; the price is put on an ordinary-share basis before it meets the share count. Provenance.
Fundamentals
| From the 20-F for the year ended 2025-12-31 | USD | As reported |
|---|---|---|
| Net incomeifrs-full:ProfitLoss | $10.2bn | |
| Research & developmentifrs-full:ResearchAndDevelopmentExpense | $14.2bn | |
| Total assetsifrs-full:Assets | $114.1bn |
Market cap / net income 24.6× — a market value from 2026-08-28 divided by earnings for a year that ended 2025-12-31. The two dates are far apart on purpose: this is arithmetic on two published numbers, not a valuation.
Every figure above is read from the same 20-F, filed 2026-02-24, and each row names the XBRL tag it came from so it can be checked against the document. Metrics absent from that filing are absent here rather than sourced from a different year — a table mixing periods is individually true and collectively meaningless.
Identifier crosswalk
| Standard | Value | What it answers |
|---|---|---|
| Ticker | AZN | Venue-local shorthand — ambiguous across markets |
| MIC | XLON | ISO 10383 — the venue |
| ISIN | GB0009895292 | ISO 6166 — the security |
| LEI | PY6ZZQWO2IZFZC3IOL08 | ISO 17442 — the legal entity |
| FIGI | BBG001SCNW31 | OpenFIGI — instrument, share class |
5 naming systems for one entity — only codes we actually hold are listed, with no gaps filled by guessing. Sources: LEI from GLEIF (CC0), ISIN read from the issuer's own primary listing document, with its ISO 6166 check digit validated, FIGI from OpenFIGI (open standard), MIC from the ISO 10383 registry. Each linked code opens its reverse-lookup page; the validator checks any code's check digit. seed-0.7 · marketcap-1 · 2026-08-30.
Approximate reference values from public sources · seed-0.7 · marketcap-1 · 2026-08-30 · not real-time. See data & methodology.
JSONCSV No key, CORS enabled — paste any of these straight into a notebook.